KureCare is expanding its Medicare-covered wound treatment access ahead of January 2026 CMS reimbursement changes. New site-neutral payment models and stricter documentation requirements will reshape chronic wound care for diabetic foot ulcers, venous leg ulcers, and pressure sores.

Miami, United States, November 26, 2025 -- The recent KureCare expansion comes ahead of significant reimbursement changes affecting individuals with non-healing venous leg ulcers, diabetic foot ulcers, pressure sores, and surgery wounds. KureCare, a division of Veracor Group LLC, offers Medicare-covered regenerative treatments that heal wounds up to 90 percent faster than some traditional options.

Interested parties can learn more at https://curewounds.com

Beginning January 1, 2026, the Centers for Medicare & Medicaid Services will implement new updates affecting wound care and skin substitute products, regulatory shifts that have been spurred by exponential cost growth. Between 2019 and 2024, Medicare Part B spending on cellular and tissue-based products skyrocketed from $256 million to more than $10 billion, according to claims data.

The new rules will require providers to justify the medical necessity for every application and demonstrate clear progress using detailed wound assessments. They will also require providers to demonstrate that conservative treatments have failed before applying cellular or tissue-based products. KureCare's treatments are designed to align with these increased documentation standards, but patients are encouraged to verify their eligibility and the cost implications before January for better planning.

The upcoming changes will reshape the way providers deliver care to patients with diabetic foot ulcers, venous leg ulcers, and pressure sores, as well as coverage for these patients. In response, KureCare encourages patients with non-healing wounds like these to begin investigating advanced regenerative treatment now, before the new rules take effect.

The company pursues different treatment approaches and outcomes depending upon the type of wound being treated. Treatments for diabetic foot ulcers typically prevent amputations, speeding healing by 90 percent. Management of venous leg ulcers, which often occur around the ankle, improves circulation and reduces ulcer recurrence.

Addressing pressure injuries, also known as bed sores, promotes pain reduction and better tissue repair, while treatment for slow-healing post-surgical wounds enhances recovery and reduces scarring.

KureCare's regenerative wound solutions, which typically use amniotic skin grafts, accelerate healing and improve patient outcomes compared to many traditional methods. This makes the company's treatments an attractive alternative, considering Medicare's new emphasis on measurable healing and outcome-driven care. Still, the team notes, other changes could affect affordability, and patients are urged to keep abreast of developments as they unfold.

For more information, please visit https://curewounds.com

Contact Info:
Name: Kenton Gray
Email: Send Email
Organization: Kure Care a division of Veracor Group LLC
Address: 1150 NW 72ND AVE TOWER 1 STE 455 #20073 , Miami, FL 33126, United States
Website: https://curewounds.com

Source: PressCable

Release ID: 89177043

If there are any problems, discrepancies, or queries related to the content presented in this press release, we kindly ask that you notify us immediately at error@releasecontact.com (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our responsive team will be available round-the-clock to address your concerns within 8 hours and take necessary actions to rectify any identified issues or support you with press release takedowns. Ensuring accurate and trustworthy information is our unwavering commitment.